Biologics in patients with skin diseases - 27/09/17
Doi : 10.1016/j.jaci.2017.03.012
Mylène S. Veilleux, MD a, Neil H. Shear, MD b, ⁎ 
a Hôtel-Dieu de Lévis Hospital and Laval University, Department of Medicine, Division of Dermatology, Quebec City, Quebec
b Sunnybrook Health Sciences Centre and University of Toronto, Department of Medicine, Division of Dermatology, Toronto, Ontario, Canada
∗Corresponding author: Neil H. Shear, MD, Sunnybrook Health Sciences Centre and University of Toronto, Department of Medicine, Division of Dermatology, Rm M1-700, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada.Sunnybrook Health Sciences Centre and University of TorontoDepartment of MedicineDivision of DermatologyRm M1-700, 2075 Bayview AveTorontoOntarioM4N 3M5Canada
Abstract |
Biologic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous diseases. Monoclonal antibodies already in use or under investigation are targeted for psoriasis, atopic dermatitis, melanoma, hidradenitis suppurativa, and pemphigus vulgaris.
Le texte complet de cet article est disponible en PDF.Key words : Biologics, mAbs, pemphigus, psoriasis, eczema, hidradenitis suppurativa, melanoma
Abbreviations used : CTLA-4, FDA, HS, NK, PAPA, PASH, PASI, PD-1, PD-L1
Plan
| Disclosure of potential conflict of interest: N. H. Shear has consultant arrangements with and has received payment for lectures from Janssen, Roche, Novartis, Valeant, Sanofi Genzyme, Eli Lilly, Celgene, and Amgen. M. S. Veilleux declares no relevant conflicts of interest. |
|
| Terms in boldface and italics are defined in the glossary on page 1424. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1423-1430 - mai 2017 Retour au numéro
Article précédent
- Biologics and biomarkers for asthma, urticaria, and nasal polyposis
- Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
- Bradley E. Chipps, Bob Lanier, Henry Milgrom, Antoine Deschildre, Gunilla Hedlin, Stanley J. Szefler, Meyer Kattan, Farid Kianifard, Benjamin Ortiz, Tmirah Haselkorn, Ahmar Iqbal, Karin Rosén, Benjamin Trzaskoma, William W. Busse
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?